Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Joris C Verster
Thomas Roth

Sleep

Showing results (1-10 of 64) with videos related to

Pageof 7
Sort By:
Sleep|October 4, 2011
Next-day effects of ramelteon (8 mg), zopiclone (7.5 mg), and placebo on highway driving performance, memory functioning, psychomotor performance, and mood in healthy adult subjectsMonique A J Mets, Juna M de Vries, Lieke M de Senerpont Domis, et al.
Sleep|May 16, 2018
Insomnia as a path to alcoholism: tolerance development and dose escalationTimothy Roehrs, Thomas Roth
Sleep|October 17, 2006
An epidemiologic study of sleep-disordered breathing symptoms among adolescentsEric O Johnson, Thomas Roth
Sleep|September 16, 2008
Periodic limb movements during sleep: population prevalence, clinical correlates, and racial differencesHolly Scofield, Thomas Roth, Christopher Drake
Sleep|September 30, 2004
Risk-taking behavior: effects of ethanol, caffeine, and basal sleepinessTimothy Roehrs, Mark Greenwald, Thomas Roth
Sleep|October 18, 2014
The nature of stable insomnia phenotypesVivek Pillai, Thomas Roth, Christopher L Drake
Sleep|August 10, 2006
The prevalence of multiple sleep-onset REM periods in a population-based sampleMeeta Singh, Christopher L Drake, Thomas Roth
Sleep|March 24, 2006
Effect of tiagabine on sleep in elderly subjects with primary insomnia: a randomized, double-blind, placebo-controlled studyThomas Roth, Kenneth P Wright, James Walsh
Sleep|September 22, 2005
Ramelteon (TAK-375), a selective MT1/MT2-receptor agonist, reduces latency to persistent sleep in a model of transient insomnia related to a novel sleep environmentThomas Roth, Charlene Stubbs, James K Walsh
Sleep|November 2, 2012
Efficacy of eight months of nightly zolpidem: a prospective placebo-controlled studySurilla Randall, Timothy A Roehrs, Thomas Roth
Pageof 7

Showing results (1-10 of 64) with videos related to

Sort By:
Pageof 7
Sleep|October 4, 2011
Next-day effects of ramelteon (8 mg), zopiclone (7.5 mg), and placebo on highway driving performance, memory functioning, psychomotor performance, and mood in healthy adult subjectsMonique A J Mets, Juna M de Vries, Lieke M de Senerpont Domis, et al.
Sleep|May 16, 2018
Insomnia as a path to alcoholism: tolerance development and dose escalationTimothy Roehrs, Thomas Roth
Sleep|October 17, 2006
An epidemiologic study of sleep-disordered breathing symptoms among adolescentsEric O Johnson, Thomas Roth
Sleep|September 16, 2008
Periodic limb movements during sleep: population prevalence, clinical correlates, and racial differencesHolly Scofield, Thomas Roth, Christopher Drake
Sleep|September 30, 2004
Risk-taking behavior: effects of ethanol, caffeine, and basal sleepinessTimothy Roehrs, Mark Greenwald, Thomas Roth
Sleep|October 18, 2014
The nature of stable insomnia phenotypesVivek Pillai, Thomas Roth, Christopher L Drake
Sleep|August 10, 2006
The prevalence of multiple sleep-onset REM periods in a population-based sampleMeeta Singh, Christopher L Drake, Thomas Roth
Sleep|March 24, 2006
Effect of tiagabine on sleep in elderly subjects with primary insomnia: a randomized, double-blind, placebo-controlled studyThomas Roth, Kenneth P Wright, James Walsh
Sleep|September 22, 2005
Ramelteon (TAK-375), a selective MT1/MT2-receptor agonist, reduces latency to persistent sleep in a model of transient insomnia related to a novel sleep environmentThomas Roth, Charlene Stubbs, James K Walsh
Sleep|November 2, 2012
Efficacy of eight months of nightly zolpidem: a prospective placebo-controlled studySurilla Randall, Timothy A Roehrs, Thomas Roth
Pageof 7